Dendritic cell type determines the mechanism of bystander suppression by adaptive T regulatory cells specific for the minor antigen HA-1

Journal of Immunology

Volumn 179, Issue 6, 2007, Pages 3443-3451

  Derks, Richard A ^a,b   Jankowska Gan, Ewa ^a   Xu, Qingyong ^a   Burlingham, William J ^a,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HA 1 ANTIGEN; HISTOCOMPATIBILITY ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; EPITOPE; HA-1 ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; OLIGOPEPTIDE; VIRUS ANTIGEN;

ARTICLE; BONE MARROW CELL; BYSTANDER EFFECT; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ADAPTATION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CLASSIFICATION; COCULTURE; CROSS PRESENTATION; CYTOLOGY; DELAYED HYPERSENSITIVITY; ENZYME ACTIVATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; KIDNEY TRANSPLANTATION; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANTIGENS, VIRAL; BYSTANDER EFFECT; CELLS, CULTURED; COCULTURE TECHNIQUES; CROSS-PRIMING; DENDRITIC CELLS; ENZYME ACTIVATION; EPITOPES, T-LYMPHOCYTE; HERPESVIRUS 4, HUMAN; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KIDNEY TRANSPLANTATION; MICE; MICE, SCID; MINOR HISTOCOMPATIBILITY ANTIGENS; OLIGOPEPTIDES; T-LYMPHOCYTES, REGULATORY;

EID: 35748940007     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.6.3443     Document Type: Article

References (48)

1. Bullock, W. W., D. H. Katz, and B. Benacerraf. 1975. Induction of T-lymphocyte responses to a small molecular weight antigen. III. T-T cell interactions to determinants linked together: suppression vs. enhancement. J. Exp. Med. 142: 275-287.
2. Niederkorn, J. Y., and J. W. Streilein. 1983. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses. J. Immunol. 131: 2670-2674.
3. Niederkorn, J. Y., E. Mayhew, and Y. He. 1995. Alloantigens introduced into the anterior chamber of the eye induce systemic suppression of delayed hypersensitivity to third-party alloantigens through "linked recognition". Transplantation 60: 348-354.
4. Streilein, J. W., S. Masli, M. Takeuchi, and T. Kezuka. 2002. The eye's view of antigen presentation. Hum. Immunol. 63: 435-443.
5. Davies, J. D., L. Y. Leong, A. Mellor, S. P. Cobbold, and H. Waldmann. 1996. T cell suppression in transplantation tolerance through linked recognition. J. Immunol. 156: 3602-3607.
6. Miller, A., O. Lider, and H. L. Weiner. 1991. Antigen-driven bystander suppression after oral administration of antigens. J. Exp. Med. 174: 791-800.
7. VanBuskirk, A. M., M. E. Wakely, J. H. Sirak, and C. G. Orosz. 1998. Patterns of allosensitization in allograft recipients: long-term cardiac allograft acceptance is associated with active alloantibody production in conjunction with active inhibition of alloreactive delayed-type hypersensitivity. Transplantation 65: 1115-1123.
8. + T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway. Immunity 11: 463-472.
9. Bluestone, J. A., and A. K. Abbas. 2003. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3: 253-257.
10. Tang, Q., J. Y. Adams, A. J. Tooley, M. Bi, B. T. Fife, P. Serra, P. Santamaria, R. M. Locksley, M. F. Krummel, and J. A. Bluestone. 2006. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat. Immunol. 7: 83-92.
11. + T cells, and HA-1 microchimerism, in allograft tolerance. J. Exp. Med. 199: 1017-1023.
12. Qingyong, X. U., J. Lee, E. Jankowska-Gan, J. Schultz, D. Roenenburg, L. D. Haynes, S. Kusaka, H. W. Sollinger, S. J. Knechtle, A. M. VanBuskirk, et al. 2007. Human CD4-positive CD25-low adaptive T regulatory cells suppress delayed type hypersensitivity during transplant tolerance. J. Immunol. 178: 3983-3995.
13. + T regulatory cell infiltrates. J. Immunol. 172: 5753-5764.
14. Shortman, K., and Y. J. Liu. 2002. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2: 151-161.
15. Ochando, J. C., C. Homma, Y. Yang, A. Hidalgo, A. Garin, F. Tacke, V. Angeli, Y. Li, P. Boros, Y. Ding, et al. 2006. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat. Immunol. 7: 652-662.
16. Mazariegos, G. V., A. F. Zahorchak, J. Reyes, L. Ostrowski, B. Flynn, A. Zeevi, and A. W. Thomson. 2003. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am. J. Transplant. 3: 689-696.
17. Burlingham, W., E. Jankowska-Gan, A. M. VanBuskirk, R. P. Pelletier, and C. G. Orosz. 2005. Measuring immunity. In Delayed Type Hypersensitivity Responses, Ch. 35. M. T. Lotze and A. W. Thomson, Elsevier Academic Press, London, pp. 407-418.
18. Carrodeguas, L., C. G. Orosz, W. J. Waldman, D. D. Sedmak, P. W. Adams, and A. M. VanBuskirk. 1999. Trans vivo analysis of human delayed-type hypersensitivity reactivity. Hum. Immunol. 60: 640-651.
19. Geissler, F., E. Jankowska-Gan, H. Sollinger, M. Kalayoglu, A. M. VanBuskirk, C. G. Orosz, and W. Burlingham. 2001. Immunoregulation in liver transplant recipients: possible evidence of tolerance by DTH assay. Transplant. Proc. 33: 1377.
20. Burlingham, W. J., and E. Jankowska-Gan. 2007. Mouse strain and injection site are crucial for detecting linked suppression in transplant recipients by trans-vivo DTH assay. Am. J. Transplant. 7: 466-470.
21. Matin, A., I. M. Streete, I. M. Jamie, R. J. Truscott, and J. F. Jamie. 2006. A fluorescence-based assay for indoleamine 2,3-dioxygenase. Anal. Biochem. 349: 96-102.
22. Hwu, P., M. X. Du, R. Lapointe, M. Do, M. W. Taylor, and H. A. Young. 2000. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164: 3596-3599.
23. Mellor, A. L., P. Chandler, B. Baban, A. M. Hansen, B. Marshall, J. Pihkala, H. Waldmann, S. Cobbold, E. Adams, and D. H. Munn. 2004. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol. 16: 1391-1401.
24. Wieles, B., J. Pool, R. Derks, W. J. Burlingham, and E. Goulmy. 2005. Detection of microchimerism by minor histocompatibility antigen HA-1 allele-specific nested polymerase chain reaction. Biol. Blood Marrow Transplant. 11: 345-348.
25. Masli, S., B. Turpie, and J. W. Streilein,. 2006. Thrombospondin orchestrates the tolerance-promoting properties of TGFβ-treated antigen-presenting cells. Int. Immunol. 18: 689-699.
26. Doyen, V., M. Rubio, D. Braun, T. Nakajima, J. Abe, H. Saito, G. Delespesse, and M. Sarfati. 2003. Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation. J. Exp. Med. 198: 1277-1283.
27. Crawford, S. E., V. Stellmach, J. E. Murphy-Ullrich, S. M. Ribeiro, J. Lawler, R. O. Hynes, G. P. Boivin, and N. Bouck. 1998. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 93: 1159-1170.
28. Annis, D. S., J. E. Murphy-Ullrich, and D. F. Mosher. 2006. Function-blocking antithrombospondin-1 monoclonal antibodies. J. Thromb. Haemost. 4: 459-468.
29. McCurry, K. R., B. L. Colvin, A. F. Zahorchak, and A. W. Thomson. 2006. Regulatory dendritic cell therapy in organ transplantation. Transpl. Int. 19: 525-538.
30. Min, W. P., D. Zhou, T. E. Ichim, G. H. Strejan, X. Xia, J. Yang, X. Huang, B. Garcia, D. White, P. Dutartre, et al. 2003. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J. Immunol. 170: 1304-1312.
31. + T cells and dendritic cells in vivo. J. Exp. Med. 203: 505-511.
32. Ito, T., M. Yang, Y. H. Wang, R. Lande, J. Gregorio, O. A. Perng, X. F. Qin, Y. J. Liu, and M. Gilliet. 2007. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J. Exp. Med. 204: 105-115.
33. Mellor, A. L., and D. H. Munn. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4: 762-774.
34. Platten, M., P. P. Ho, S. Youssef, P. Fontoura, H. Garren, E. M. Hur, R. Gupta, L. Y. Lee, B. A. Kidd, W. H. Robinson, et al. 2005. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310: 850-855.
35. + T cells. J. Immunol. 168: 2247-2254.
36. hi T cell responses to the same antigen. Eur. J. Immunol. 36: 397-410.
37. + T regulatory cells. J. Immunol. 177: 6091-6097.
38. + regulatory T cell activity in both humans and mice. J. Immunol. 172: 834-842.
39. high-induced colitis by a TGF-β-dependent mechanism. J. Immunol. 170: 2516-2522.
40. Li, Z., L. He, K. Wilson, and D. Roberts. 2001. Thrombospondin-1 inhibits TCR-mediated T lymphocyte early activation. J. Immunol. 166: 2427-2436.
41. Li, M. O., Y. Y. Wan, S. Sanjabi, A. K. Robertson, and R. A. Flavell. 2006. Transforming growth factor-β regulation of immune responses. Annu. Rev. Immunol. 24: 99-146.
42. Li, M. O., S. Sanjabi, and R. A. Flavell. 2006. Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25: 455-471.
43. Stein-Streilein, J., and J. W. Streilein. 2002. Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy. Int. Rev. Immunol. 21: 123-152.
44. Marteau, F., N. S. Gonzalez, D. Communi, M. Goldman, J. M. Boeynaems, and D. Communi. 2005. Thrombospondin-1 and indoleamine 2,3-dioxygenase are major targets of extracellular ATP in human dendritic cells. Blood 106: 3860-3866.
45. Derks, R., and K. Beaman. 2004. Regeneration and tolerance factor modulates the effect of adenosine triphosphate-induced interleukin 1 β secretion in human macrophages. Hum. Immunol. 65: 676-682.
46. Mutis, T., G. Gillespie, E. Schrama, J. H. Falkenburg, P. Moss, and E. Goulmy. 1999. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat. Med. 5: 839-842.
47. Beutelspacher, S. C., P. H. Tan, M. O. McClure, D. F. Larkin, R. I. Lechler, and A. J. George. 2006. Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses. Am. J. Transplant. 6: 1320-1330.
48. de Bueger, M., A. Bakker, J. J. Van Rood, F. Van der Woude, and E. Goulmy. 1992. Tissue distribution of human minor histocompatibility antigens: ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J. Immunol. 149: 1788-1794.